Age-related dementias are projected to cost the global economy $130T over the next 20 years, with Parkinson’s disease as the fastest-growing neurodegenerative disorder. A multi-year gap between disease onset and symptom presentation delays clinical diagnosis, limits the development and effectiveness of therapeutics, and ultimately contributes to drug trial failure due to poor patient stratification.

Priogen’s seed amplification assay technology enables detection of Parkinson’s disease years before symptom onset. Our integrated platform—combining hardware and reagents—provides data that pharmaceutical companies can use for strategic patient cohort selection, accelerating the development of breakthrough therapies.

We have an innovative, diverse, and highly productive founding team that has worked together for 7 years, with support from experienced advisors who collectively bring 75+ years of startup experience . Our core values are: 1) Function as a team, 2) Communicate openly and honestly, 3) Work with dedication, 4) Innovate with purpose, 5) Swift execution yields results.

We have established the foundation for a formidable corporation poised to lead the seed amplification assay industry. Our achievements include a solid revenue stream, an expanding customer base, numerous technological breakthroughs, functional prototypes, diverse product offerings, secured funding from venture capitalists and private investors, and a strategic, methodical rollout of services and technologies.